Talk:Teriparatide

I have just been prescribed Forteo for early and substantial bone loss. Who has been taking this and what statistics/results have you had? How are the side affects?````

Reply to above, 2/18/2008: I took Forteo for 10 months when I was 60 after I stopped showing gains in bone density from Fosamax. After 10 months I showed only regression with Forteo, so I stopped it and returned to Fosamax. I am a man btw with no known risk factors for osteoporosis, but mine is fairly severe. —Preceding unsigned comment added by 64.47.82.42 (talk) 21:22, 18 February 2008 (UTC)

=required= the page should have a heading 'contraindications' and another 'side effects'. Contraindications: those with Paget's Disease of the bone, patients with unexplained elevations in alkaline phoshatase levels, and pregnant/breast feeding mothers.accessed from (www.forteo.com) and www.epocrates.com on 21st oct 2008. Najafhaider (talk) 15:18, 21 October 2008 (UTC)

My name is German Guerrero, MD, and I am Senior Medical Director, Global Medical Affairs at Radius Health, Inc., a biopharmaceutical company based out of Waltham, MA. I'm here to flag misinformation that is currently included on the Teriparatide page.

I am aware of Wikipedia's policies and guidelines, including those on WP:COI, WP:RS, WP:V and WP:NPOV, and I will abide by them. My edit suggestions will be restricted to Talk pages, and I will not engage in directly editing any teriparatide-related article. On any pages where I may suggest changes, I will be sure to disclose my relationship to Radius Health in the interest of transparency.

If you have any questions about my editing activities, please leave me a message on my User Talk page.

Revisions to Teriparatide page
Current:

Medical uses
Teriparatide is the only anabolic (i.e., bone growing) agent[1] indicated for use in postmenopausal women with osteoporosis at a high risk for fracture or with a history of osteoporotic fracture, patients with multiple risk factors for fracture, and for patients who have failed or are intolerant to other available osteoporosis therapy.[4] It has been FDA-approved since 2002.[5] It is effective in growing bone (e.g., 8% increase in bone density in the spine after one year)[6] and reducing the risk of fragility fractures.[5][7] Osteoporosis medications are generally safe, but some side effects of teriparatide include headache, nausea, dizziness, and limb pain.[5]

Revised:
 * Updating the first sentence of the first paragraph under the “Medical uses” section to correct the fact that there is now more than one anabolic agent approved for the treatment of postmenopausal women with osteoporosis

Medical uses
Teriparatide is one of two available anabolic (i.e., bone growing) agents[1] indicated for use in postmenopausal women with osteoporosis at a high risk for fracture or with a history of osteoporotic fracture, patients with multiple risk factors for fracture, and for patients who have failed or are intolerant to other available osteoporosis therapy.[4] It has been FDA-approved since 2002.[5] It is effective in growing bone (e.g., 8% increase in bone density in the spine after one year)[6] and reducing the risk of fragility fractures.[5][7] Osteoporosis medications are generally safe, but some side effects of teriparatide include headache, nausea, dizziness, and limb pain.[5]